EVIO Inc (OTCMKTS:EVIO) reported the appointment of Mr. Al Lustig as President of company, reporting to CEO William Waldrop. Lustig’s major responsibility will be to lead company’s growth in both existing and new markets by executing and developing national and international operational strategies and sales.
Lustig joins EVIO post completing a successful career at Pfizer Inc (NYSE:PFE). Lustig joined Pfizer as a Professional Sales Representative in in 1986 and later quickly ascended to roles of increased responsibility, becoming a State Director. During his role at Pfizer, Lustig led, helped and built manage several regional, national and district sales firms that consistently surpassed all performance outlooks.
Lustig redefined conventional business models that led in the successful launches of innovative and new pharmaceuticals, generating billions in sales and enhancing the lives of many patients. While at Pfizer, he even led several cross functional teams and associated with senior leadership to support integrate Sales, Operations, Strategy & Analytics, Government, Marketing and Medical Relations across business operations.
Waldrop, the CEO of EVIO, reported that as they embark upon their next phase of fast growth, Al’s history of known success in sales leadership and corporate growth at Pfizer, one of the largest bio-pharmaceutical firms across the world, makes him an ideal fit to help direct EVIO into 2018 and beyond. They look forward to using Al’s expertise and leadership from the pharmaceutical segment. Current EVIO Chief Operating Officer and President Lori Glauser has resigned from her role as President to pave way for Lustig in the Senior Leadership team. Glauser will remain with the firm as Chief Operating Officer, heading both company’s laboratory expansion and advisory services division.
In the last trading session, the stock price of EVIO jumped more than 10% to close the day at $2.16. The gains came at a share volume of 176,030 compared to average share volume of 141,794.
Insys Therapeutics Inc (NASDAQ:INSY) Issues An Update on CBD Pharmaceuticals and Spray Technology Products
Insys Therapeutics Inc (NASDAQ:INSY) has issued an update on the naloxone nasal and epinephrine sprays and CBD oral solutions. CEO and President of Insys Therapeutics, Saeed Motahari said the company is focusing on novel drug delivery systems and pharmaceutical grade cannabinoids to drive the growth going forward. It is moving away from opioids. The company is transforming its business strategy to include patient-centric formulations over the past one year. Going forward, Insys Therapeutics is preparing to submit 6 innovative drug applications in the next 3 years. The company is scheduling two of them in 2019.
An update on the Opioid Related Assets
As per the announced plans, Insys Therapeutics is scheduling the alternative review of the opioid related assets. As of now, nine firms have entered into a pact with Insys Therapeutics and are reviewing the confidential information. The company will release an update on this aspect in early 2019.
An Update on the Lifesaving Products
Insys Therapeutics is in the advanced stages of developing the lifesaving investigational products that are based on spray technologies. Its lifesaving products in development include epinephrine nasal spray for anaphylaxis and naloxone nasal spray for the opioid overdose.
The company is also focusing on cannabinoids like CBD oral solution targeting the child absence epilepsy treatment (phase 2), Prader Willi Syndrome (phase 2), infantile spasms (phase 3), and dronabinol inhalation to treat a variety of conditions such as anorexia in patients suffering from cancer.
Insys Therapeutics is conducting a non-clinical toxicity study on naloxone nasal spray and expects to announce the results in March 2019. The company has set the timeframe for the NDA submission in Q1 2019.
Epinephrine nasal spray, which is intended for needle-free delivery, is a substitute to the intramuscular injection. According to the study, it is readily absorbed via the nasal mucosa. The company has obtained FDA nod for fast track designation for the drug in August 2018. It has also provided specific guidelines for filing requirement and clinical development. Insys Therapeutics is optimistic to complete the filing requirements for epinephrine NDA in Q4, 2019. It is subject to successful completion of PK study.
The company has successfully completed a proof of concept study on dronabinol inhalation in September 2018. Insys Therapeutics will arrange a meeting with clinical experts in Q1 2019 to discuss further development for this investigational formulation.
Insys Therapeutics Signs a Pact with Lunatus for Commercializing SUBSYS
Insys Therapeutics has signed a definitive accord with Lunatus for commercializing Subsys in 8 nations in the Middle East. Following the deal, Lunatus will act as an authorized agent and licensee in the UAE, Lebanon, Kuwait, Jordan, Saudi Arabia, Qatar, Oman, and Bahrain.
International Consolidated Inc (OTCMKTS:INCC) Pronounces A $5 Million Dollar Institutional Offer
International Consolidated Inc (OTCMKTS:INCC) is quite pleased to make the announcement that obtained an institutional offer worth $5 million dollars from the IFG Opportunity Fund LLC. According to a person well conversant with the matter, it happened prior to the company becoming fully reporting.
The business guru is making plans to move ahead and execute its business plan and it is crucial to mention the point that the undertaking served them with about three 3 additional options for funding.
The company’s take on business operations
It was way back in 2004 that the IFG Opportunity Fund, LLC began as a private equity fund set up to make investments in the series of the small growth companies via the PIPE’s which are fundamentally private investments in public equities.
They invest in their own capital and that of course indicates more flexibility as well as a greater competitive advantage at a time when business dynamics tend to be shifting quite fast. Competitive pricing is a point that the business giant takes with much seriousness and market observers have termed that a great way to move about business.
The water-soluble CBD oil super food and expert strategies
The water-soluble CBD oil super food and wellness drinks that are being introduced by BluDog Products are easily absorbed. And they are the perfect alternative for over-the-counter therapeutic option that helps promote well being and relaxation.
Asides from that they play a significant role helping relieve post-sports inﬂammation not forgetting that the CBD products naturally interact with the anti-inﬂammatory system of the body and there are no associated side effects.
The Managing Member of BluDog Products LLC Antonio Uccello while moving out of a business conference addressed news reporters telling them that as a company they were quite pleased about getting to the point of providing high quality BluDog Products.
Much has been happening in the recent years, one of the things being the acquisition of the American Nutritional Products Inc. Several market analysts have said that the company is placing itself on the right path in the quest to achieve monumental success in a market characterized with stiff competition.
Premier Biomedical Inc (OTCMKTS:BIEI) Searches For Development Partner To Develop Patent Pending Technology
Premier Biomedical Inc (OTCMKTS:BIEI) reported that they are actively looking for an associate to advance their patented extracorporeal treatment procedure in together with their patent pending process for treating ailments through the application of lasers.
The methodology uses the concept of curing the blood outside the human body in a continuous flow procedure, together with an emissive energy means, such as a laser, to destroy directed antigens in the blood, before returning the blood to the person. The firm has exceptional privileges to three dispensed patents, one provisional patent application and six pending applications, all related to unique treatments for cancer as well as extracorporeal treatments for different life-threatening ailments.
Dr. Felder, the Inventor of the underlying technologies, expressed that the application of lasers in conjunction with their extracorporeal treatment procedure is a thrilling concept, as it should eliminate any infectious ailment, without the probability of pathogen resistance, or the action of side effects from the therapy. It also has the prospect for being an efficacious and inexpensive treatment for septicemia — a major cause of death globally.
William A. Hartman, the CEO and President of Premier Biomedical, expressed that they consider this combination of their patented extracorporeal treatment procedure with their patent awaiting emissive energy ablation of directed antigens could pave a complete new chapter in the means diseases are cured. The efficacy and safety of treatment protocols for a broad range of ailments could be considerably improved.
Premier Biomedical marks as a research-based publicly traded firm that plans to develop and discover medical treatments for a broad range of ailments in humans. The company has obtained, through different license agreements, the know-how behind three allowed US Patents, several pending provisional patents, as well as a ‘PCT’ Europe National Patent. Premier Biomedical was established back in 2010.
Digipath Inc. (OTCMKTS: DIGP) Announce Significant Milestones On Development Of GroSciences Hemp-Test Kit
Post Views: 236 Digipath Inc. (OTCMKTS:DIGP) has announced that its GroSciences subsidiary has made substantial progress in the development of...
Harvest Health & Recreation Inc (OTCMKTS:HRVSF) Launches Expands Its Footprint In Florida With New Medical Marijuana dispensary in Gainesville
Post Views: 258 Harvest Health & Recreation Inc (OTCMKTS:HRVSF) recently announced that it launched a new outlet in Gainesville, making...
Harvest Health & Recreation Inc (OTCMKTS:HRVSF) Gets Greenlight To Expand Its Foreign Private ISSUER Threshold
Post Views: 232 Harvest Health & Recreation Inc (OTCMKTS:HRVSF) revealed earlier this month that its Board of Directors has approved...
Generex Biotechnology Corporation (OTCMKTS:GNBT) Adds MediSource Partners And Pantheon Medical To Its NuGenerex Family Of Subsidiaries
Post Views: 168 Generex biotechnology Corporation (OTCMKTS:GNBT) has welcomed MediSource Partners to its family of subsidiaries and introduced Pantheon Medical...
CBD Unlimited Inc. (OTCMKTS:EDXC) Enhances Its Convenience Store Program Targeting 300 Stores
Post Views: 174 CBD Unlimited Inc. (OTCMKTS:EDXC), formerly Endexx Corporation, has announced an enhanced convenient store launch program. The provider...
Cronos Group Inc. (NASDAQ:CRON) Spends $300 Million On CBD Skincare Businesses
Post Views: 167 Cronos Group Inc. (NASDAQ:CRON) has not had the best of runs in recent months, after starting the...
Elev8 Brands, Inc. (OTCMKTS:VATE) A Potential Break Out Play On Sales Growth Boost
Post Views: 125 Elev8 Brands, Inc. (OTCMKTS:VATE) stock is a potential break out play as a flurry of positive developments...
Medical Marijuana Inc. (OTCMKTS:MJNA) Eyes Fresh Gains On Improving Fundamentals
Post Views: 81 Medical Marijuana Inc. (OTCMKTS:MJNA) bounce back from all-time lows continues to gather pace on improving fundamentals. Investor’s...
Sugarmade Inc. (OTCMKTS:SGMD) Turns To Hemp Production To Reinvigorate Growth Prospects
Post Views: 95 Sugarmade Inc. (OTCMKTS:SGMD) has made a strategic investment in Hempistry as it tries to reinvigorate its growth...
Auxly Cannabis Group Inc (OTCMKTS:CBWTF) Acquires 46% Stake In Curative Cannabis And Agrees to Fund Cannabis Cultivation Facility To Produce Ultra Premium Cannabis
Post Views: 47 Auxly Cannabis Group Inc (OTCMKTS:CBWTF) has entered a deal to take over a 46% stake in Curative...
Health3 years ago
Medical Marijuana Inc (OTCMKTS:MJNA) Enters Mexico With Hemp Oil
PROFILES11 months ago
Could PLSI Be Poised to Dominate the International Cannabis Market?
Uncategorized2 years ago
Study Unveils Hemp Could Treat These 10 Chronic Conditions
PROFILES11 months ago
For the Next Wave of Marijuana Profits, Look to Real Estate
PROFILES10 months ago
California cannabis stocks take off after new July 1 regulations
Business10 months ago
Aurora Cannabis Inc (NYSE:ACB) Sets Out for Global Domination with ICC Move
Business2 years ago
Will McKesson Make Maricann Canada’s Next Unicorn Stock?
Business11 months ago
New Age Beverages Corp (NASDAQ:NBEV) Gears Up for a Big Week